Patents by Inventor Christopher Thanos

Christopher Thanos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250025210
    Abstract: Macroencapsulation implantation devices and containers for storing a macroencapsulation device disposed within a receptacle of a macroencapsulation implantation device as well as related methods are described. In some embodiments, a macroencapsulation implantation device may include a handle that is configured to be selectively engaged with a receptacle including a recess in which a macroencapsulation device may be disposed. In some embodiments, a container may be configured to maintain a receptacle of a macroencapsulation implantation device, and a macroencapsulation device disposed therein, in a desired pose within an internal volume of the container.
    Type: Application
    Filed: July 19, 2024
    Publication date: January 23, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Megan Billings, John Mills, John Fraser Mills, Noah Nguyen, Christopher Thanos
  • Patent number: 12194138
    Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: January 14, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Yang Qiu
  • Publication number: 20240425817
    Abstract: Provided herein are, inter alia, compositions and methods for improved production of SC-? cells in vitro. For example, provided are novel formulations and differentiation methods that result in higher cell yields and recoveries, increased numbers and relative percentages of SC-? cells, enhanced stability and shelf-life of SC-? cells, SC-islet clusters with advantageous characteristics such as reduced size and increased uniformity, improved function of the SC-? cells in vitro, and improved viability, function, and reduced immunogenicity after transplantation. The disclosed compositions and methods can be employed in the manufacture of SC-islets for human therapeutic use.
    Type: Application
    Filed: December 28, 2021
    Publication date: December 26, 2024
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Bryce CAREY, Aleksander SZYMANIAK, Christopher THANOS
  • Publication number: 20240382532
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Application
    Filed: April 26, 2024
    Publication date: November 21, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
  • Publication number: 20240352392
    Abstract: Macroencapsulation devices and related methods of manufacture are described where bonded membranes of a device may be mounted to an associated frame in an arrangement to provide stress relief between the frame and a seal perimeter of the bonded membranes. The seal perimeter may be arranged radially inward from an outer perimeter of the membranes such that when the membranes are mounted to a corresponding perimeter frame, the seal perimeter is spaced radially inwards from the frame with a unbonded portion of the one or more membranes disposed between the frame and seal perimeter.
    Type: Application
    Filed: August 16, 2022
    Publication date: October 24, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, John Mills, Matthew Watson, Rahul R. Rajendran, Noah Nguyen
  • Publication number: 20240342077
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.
    Type: Application
    Filed: September 21, 2023
    Publication date: October 17, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • Patent number: 11992506
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: May 28, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
  • Publication number: 20240148642
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.
    Type: Application
    Filed: January 18, 2024
    Publication date: May 9, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: CHRISTOPHER THANOS, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • Patent number: 11951206
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: April 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • Publication number: 20240033216
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.
    Type: Application
    Filed: September 21, 2023
    Publication date: February 1, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • Publication number: 20230390400
    Abstract: A method of manufacturing a macroencapsulation device includes aligning one or more membranes of the device with a frame of the device, such that a portion of the one or more membranes overlap a portion of the frame. The method also includes deforming the one or more membranes and thermoplastically deforming the frame to form mechanically interlocked regions of the membrane and the frame.
    Type: Application
    Filed: June 6, 2023
    Publication date: December 7, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Megan Billings, Matthew Watson
  • Publication number: 20230332107
    Abstract: Disclosed herein are compositions, kits, and methods related to cell therapy for a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the methods provided herein relate to administration of non-native pancreatic cells to subject with a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the disclosure provides pharmaceutical compositions including non-native cells.
    Type: Application
    Filed: January 31, 2023
    Publication date: October 19, 2023
    Inventors: Felicia PAGLIUCA, George HARB, Jason GAGLIA, Andrea VERGANI, Christopher THANOS
  • Publication number: 20230242895
    Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Inventors: Edwin L. MADISON, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Publication number: 20230218676
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Application
    Filed: November 1, 2022
    Publication date: July 13, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
  • Patent number: 11613744
    Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Publication number: 20220331234
    Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.
    Type: Application
    Filed: May 4, 2022
    Publication date: October 20, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Yang Qiu
  • Patent number: 11471398
    Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 18, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Yang Qui
  • Publication number: 20220175511
    Abstract: The present disclosure relates to macroencapsulation devices and related methods of manufacture where the membranes of a device may be mounted to an associated frame in a relaxed, or slack, configuration prior to filling with a desired material.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 9, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, John Mills, Megan Billings
  • Publication number: 20220143374
    Abstract: Macroencapsulation devices and their methods of use are disclosed. In one embodiment, a macroencapsulation device may include a first outer membrane, a second outer membrane, and at least one semipermeable membrane disposed there between to form at least a primary compartment configured to house a first population of cells and a secondary compartment in fluid communication with the primary compartment through the first semipermeable membrane. In some embodiments, the flow of material into and out of the compartments of the macroencapsulation device and/or the application of an appropriate pressure differential between the compartments may be used to control the flow of filtrates, ancillary agents, and other materials between the compartments of the device when positioned in vivo.
    Type: Application
    Filed: April 2, 2020
    Publication date: May 12, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, John Mills, Megan Billings
  • Patent number: 11203749
    Abstract: Nucleic acids encoding modified factor VII polypeptides, vectors and cells containing the nucleic acids, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: December 21, 2021
    Assignee: CATALYST BIOSCIENCES, INC.
    Inventors: Edwin L. Madison, Christopher Thanos